NLRP3 Inhibitor KBD3536 Attenuates Acute Inflammation, Radiation-Induced Skin Injury, and Early Metabolic Dysfunction in Preclinical Models
Pharmaceuticals · 14.07.2026 · 19 (7) · 1083
DOI: 10.3390/ph19071083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 14.07.2026. Verfasst von Xinying Qian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kangbaida (Sichuan) Biotechnology Co., Ltd..
Abstract (Originalsprache)
Background
Pharmacological blockade of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has emerged as an attractive pharmacological strategy for a broad range of inflammatory and metabolic disorders. However, translating preclinical efficacy into clinical success remains a major bottleneck. We previously reported the discovery of a novel, potent NLRP3 inhibitor, KBD3536, but its in vivo efficacy across different pathological conditions remains uncharacterized. Here, we systematically evaluated the in vivo efficacy of KBD3536 across diverse preclinical models of NLRP3-related pathologies.
Methods
KBD3536 was evaluated in established rodent models of monosodium urate (MSU)-induced acute inflammation (mouse air pouch and rat gouty arthritis models), radiation-induced dermatitis (RID), and high-fat diet (HFD)-induced obesity.
Results
In the MSU models, KBD3536 markedly suppressed local interleukin-1β and interleukin-6 secretion in air pouch exudates and dose-dependently alleviated acute arthritis symptoms, including joint swelling and joint pain. In the RID model, KBD3536 significantly attenuated radiation-induced skin injury and ameliorated radiation-induced systemic weight loss. Under HFD challenge, early intervention with KBD3536 mitigated HFD-induced adiposity, early hepatic steatosis and its associated inflammatory responses, and preserved physical performance. Mechanistically, KBD3536 partially restored AMP-activated protein kinase α1 (AMPKα1) mRNA expression in adipose tissue and restored hepatic Cyp3a11 transcriptional activity.
Conclusions
NLRP3 inhibitor KBD3536 exhibited broad-spectrum anti-inflammatory efficacy across multiple preclinical models, supporting its potential as a promising candidate for diverse NLRP3-related disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- Kangbaida (Sichuan) Biotechnology Co., Ltd., Chengdu 611137, China.
ORCID-Profile: Xinying Qian, Fei Ye, Hongzhu Chu
Förderung
- Kangbaida (Sichuan) Biotechnology Co., Ltd.
Zitieren
APA
Qian, X., Ye, F., Li, Z., Chu, H., Xu, Z., Peng, W., Liang, X., Zhao, H., Tang, Y., Zhong, P., Wei, Y., & Zhao, Y. (2026). NLRP3 Inhibitor KBD3536 Attenuates Acute Inflammation, Radiation-Induced Skin Injury, and Early Metabolic Dysfunction in Preclinical Models. Pharmaceuticals, 19(7), 1083. https://doi.org/10.3390/ph19071083
Vancouver
Qian X, Ye F, Li Z, Chu H, Xu Z, Peng W, et al. NLRP3 Inhibitor KBD3536 Attenuates Acute Inflammation, Radiation-Induced Skin Injury, and Early Metabolic Dysfunction in Preclinical Models. Pharmaceuticals. 2026;19(7):1083. doi:10.3390/ph19071083
BibTeX
@article{Qian2026,
author = {Qian, Xinying and Ye, Fei and Li, Zhiyong and Chu, Hongzhu and Xu, Zeng and Peng, Wenyuan and Liang, Xueya and Zhao, Hongchuan and Tang, Yan and Zhong, Pan and Wei, Yonggang and Zhao, Yinglan},
title = {NLRP3 Inhibitor KBD3536 Attenuates Acute Inflammation, Radiation-Induced Skin Injury, and Early Metabolic Dysfunction in Preclinical Models},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {7},
pages = {1083},
doi = {10.3390/ph19071083}
}
EUVIMED